

Special Issue

Targeting Wnt Signaling in Cancer

Message from the Guest Editor

A wide variety of approaches have been used to control Wnt signaling, not only in cancer but also in other diseases where Wnt signaling has gone awry. These approaches include prevention of ligand secretion, inhibition of receptor function, modulation of effector protein stability, and disruption of transcription factor complexes. This Special Issue seeks to highlight some of the achievements that have been made in identifying drugs that target Wnt signaling, in clinical trials involving Wnt inhibitors, and in determining potential new targets and tools that might be used to impact Wnt signaling in cancer in the future. Dr. Robert M. Kypta

Guest Editor

Dr. Robert M. Kypta

Department of Surgery and Cancer, Imperial College London, London W12 0NN, UK; Centre for Cooperative Research in Biosciences, CIC bioGUNE, 48160 Derio, Spain

Deadline for manuscript submissions

closed (31 May 2019)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/17428

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)